Skip to content
Subscriber Only

Alzheimer's Research Gets Glimmer of Hope, Not for First Time

For the few drugmakers that haven’t given up on the decades-long, elusive quest for a cure of Alzheimer’s disease, each piece of news is a small signpost along a possible path to success -- and billions of dollars in potential sales.

That helps explain the 20 percent surge in Biogen Inc.’s shares Friday. After one of its experimental drugs showed disappointing results in December, a new analysis with an additional six months of data suggested that the treatment might slow the progression of the disease.